Thursday, October 23, 2014

Best Regional Bank Stocks For 2015

Best Regional Bank Stocks For 2015: Actavis Inc (ACT)

Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Actavis Pharma Segment

Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company's portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.

Actavis Specialty Brands Segment

The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company's promoted products are Rapaflo, Gelnique, Trelstar, Androderm, G! eneress Fe and Crinone. The Company's Actavis Specialty Brands segment also receives ot her revenues consisting of co-promotion revenue and royaltie! s.

Anda Distribution Segment

The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians' offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.

The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,

Advisors' Opinion:
  • [By Ben Levisohn]

    Salix Pharmaceuticals (SLXP) has jumped 5.9% to $160  on reports it was in talk to sell itself to Actavis (ACT). It was also upgraded to Neutral from Underperform at Credit Suisse.

  • [By Ben Levisohn]

    2. Actavis (ACT) settlement: Based on recent commentary by Celgene and separate RBC notes on prior Actavis mgmt meetings, we expect rational market behavior. Case discovery ends in Feb ’15 and opens the door to settlement before Court begins mid-15.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/best-regional-bank-stocks-for-2015-2.html

No comments:

Post a Comment